Skip to main content

Table 4 Percentage of 9 Classic Subsets Expressing PD-L1

From: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

PT PT3 PT7 PT11 PT14 Median of PTs HD1 HD2 Median of HDs
Days Post Tx D98 D561 D456 D596 D448
PD-L1 + CD4 1.9 1.2 1.5 1.6 1.5 1.5 0.7 0.5 0.6
PD-L1 + CD8 0.9 0.9 0.6 1.1 1.8 0.9 1.6 0.8 1.2
PD-L1 + Treg 0.3 0.1 0.8 0.6 0.6 0.6 0.2 0.1 0.2
PD-L1 + NK 3.1 1.8 1.3 1.3 1.6 1.6 1.0 0.5 0.8
PD-L1 + NKT 38.2 1.5 0.8 0.8 1.6 1.5 2.2 0.9 1.5
PD-L1 + B cells 19.45 6.75 14.12 12.83 13.14 13.1 29.32 14.00 21.7
PD-L1 + cDc 25.6 2.2 2.5 3.3 5.5 3.3 4.3 1.3 2.8
PD-L1 + pDc < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01
PD-L1 + MDSC 19.34 11.81 10.12 11.42 15.11 11.8 4.37 5.76 5.1
  1. Expression of PD-L1 in 9 classic subsets was measured by flow cytometry in 4 patients, where PBMCs were available, after treatment with durvalumab and olaparib. Results are displayed as % of classic subsets that express PD-L1. cDC conventional dendritic cells, MDSC myeloid derived suppressor cell, NK natural killer, pDC plasmacytoid DC, PD-L1 programmed cell death ligand-1, Tregs regulatory T cells